BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu F, Niu R, Shao X, Shao X. FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis. Int J Mol Med 2021;47:523-32. [PMID: 33416094 DOI: 10.3892/ijmm.2020.4816] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yue T, Cai Y, Zhu J, Liu Y, Chen S, Wang P, Rong L. Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1064704] [Reference Citation Analysis]
2 Saadi W, Fatmi A, Pallardó FV, García-Giménez JL, Mena-Molla S. Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. Cancers (Basel) 2022;15. [PMID: 36612180 DOI: 10.3390/cancers15010184] [Reference Citation Analysis]
3 Chattopadhyay P, Mishra P, Mehta P, Soni J, Gupta R, Tarai B, Budhiraja S, Pandey R. Transcriptomic study reveals lncRNA-mediated downregulation of innate immune and inflammatory response in the SARS-CoV-2 vaccination breakthrough infections. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035111] [Reference Citation Analysis]
4 Du Y, Geng G, Zhao C, Gao T, Wei B. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. BMC Cancer 2022;22:1145. [DOI: 10.1186/s12885-022-10188-0] [Reference Citation Analysis]
5 Shadbad MA, Ghorbaninezhad F, Hassanian H, Ahangar NK, Hosseinkhani N, Derakhshani A, Shekari N, Brunetti O, Silvestris N, Baradaran B. A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1027758] [Reference Citation Analysis]
6 Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Drug Resistance Updates 2022;65:100866. [DOI: 10.1016/j.drup.2022.100866] [Reference Citation Analysis]
7 Liu M, Peng J, Tang M. FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/2318170] [Reference Citation Analysis]
8 Loren P, Saavedra N, Saavedra K, De Godoy Torso N, Visacri MB, Moriel P, Salazar LA. Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review. Front Pharmacol 2022;13:831099. [PMID: 35444536 DOI: 10.3389/fphar.2022.831099] [Reference Citation Analysis]
9 Najafzadeh B, Motafakkerazad R, Najafi S, Amini M, Alemohammad H, Vasefifar P, Baradaran B. Nanog suppression enhanced the chemosensitivity of Human Non-Small-Cell Lung Cancer cells to Cisplatin and inhibited cell migration. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153869] [Reference Citation Analysis]
10 Yamaguchi H, Hsu J, Yang W, Hung M. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. [DOI: 10.1038/s41571-022-00601-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
11 Jiang W, Pan S, Chen X, Wang ZW, Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer 2021;20:116. [PMID: 34496886 DOI: 10.1186/s12943-021-01406-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
12 You H, Gao S, Xu X, Yuan H. Faciogenital dysplasia 5 confers the cancer stem cell-like traits of gastric cancer cells through enhancing Sox2 protein stability. Environ Toxicol 2021;36:2426-35. [PMID: 34427968 DOI: 10.1002/tox.23355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Amrovani M, Mohammadtaghizadeh M, Aghaali MK, Zamanifard S, Alqasi A, Sanei M. Long Non-coding RNAs: Potential Players in Cardiotoxicity Induced by Chemotherapy Drugs. Cardiovasc Toxicol 2021. [PMID: 34417760 DOI: 10.1007/s12012-021-09681-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Song K, Yu P, Zhang C, Yuan Z, Zhang H. The LncRNA FGD5-AS1/miR-497-5p axis regulates septin 2 (SEPT2) to accelerate cancer progression and increase cisplatin-resistance in laryngeal squamous cell carcinoma. Mol Carcinog 2021;60:469-80. [PMID: 34003510 DOI: 10.1002/mc.23305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
15 Liu L, Zhang C, Wang J, Liu X, Qu H, Zhang G, Liang T, Wang J, Zhang J. A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer. BMC Cancer 2021;21:453. [PMID: 33892661 DOI: 10.1186/s12885-021-08192-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]